Peptide Research Hub
Educational reference
Educational reference only. Nothing on this site is medical advice. Many compounds described here are not FDA-approved, lack adequate human evidence, and may be illegal in your jurisdiction. Always consult a licensed clinician.

Growth Hormone Secretagogues

Tesamorelin

Also known as: TH9507 Egrifta

Evidence: Strong clinical Disclaimer: Standard FDA-approved

Mechanism & research context

GHRH analog with a stabilized N-terminus. FDA-approved as Egrifta specifically for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

FDA-approved indication: HIV-associated lipodystrophy (visceral fat reduction).

Safety flags

0 flags

No curator-recorded safety flags for this entry. Absence of recorded flags is not evidence of safety. Many peptides lack adequate human data.

Research papers

15 records

Citation links route to PubMed, Europe PMC, and PMC. Presence of a study is not endorsement. Records are refreshed from PubMed on a regular cadence; rows marked “Live search link” will resolve to a current PubMed search until a full citation has been ingested.

Clinical trials

21 records
  • Live search Live search

    Live ClinicalTrials.gov search: Tesamorelin

    Condition: See live results

    Open on ClinicalTrials.gov ↗
  • NCT00257712 PHASE2 COMPLETED

    GHRH: Cognition in Aging and MCI

    Condition: Aging; Mild Cognitive Impairment

    Sponsor: University of Washington

    Open on ClinicalTrials.gov ↗
  • NCT00608023 PHASE3 COMPLETED

    A Multicenter, Double-blind, Randomized, Placebo-controlled Extension Study Assessing the Efficacy and Long-term Safety of a 2 mg Dose of TH9507, a GHRH Analog, in HIV Subjects With Excess Abdominal Fat Accumulation

    Condition: Lipodystrophy; HIV Infections

    Sponsor: Theratechnologies

    Open on ClinicalTrials.gov ↗
  • NCT00675506 PHASE2 COMPLETED

    Physiologic Effects of Long-Term GHRH1-44 in Abdominal Obesity

    Condition: Abdominal Obesity; Growth Hormone Deficiency

    Sponsor: Massachusetts General Hospital

    Open on ClinicalTrials.gov ↗
  • NCT00795210 NA COMPLETED

    Effects of Short-term Growth Hormone in HIV-infected Patients

    Condition: HIV Lipodystrophy

    Sponsor: Massachusetts General Hospital

    Open on ClinicalTrials.gov ↗
  • NCT00850564 NA COMPLETED

    Effect of Short Term Growth Hormone Releasing Hormone in Healthy Men

    Condition: Healthy Volunteers

    Sponsor: Massachusetts General Hospital

    Open on ClinicalTrials.gov ↗
  • NCT01263717 NA COMPLETED

    Effects of Growth Hormone Releasing Hormone on Fat Redistribution, Cardiovascular Indices, and Growth Hormone Secretion in HIV Lipodystrophy

    Condition: HIV; HIV Lipodystrophy

    Sponsor: Massachusetts General Hospital

    Open on ClinicalTrials.gov ↗
  • NCT01264497 PHASE2 COMPLETED

    A Double-blind, Randomized, Parallel, Placebo-controlled 12-week Evaluation of the Safety of Two Doses of TH9507 in Subjects With Stable, Type 2 Diabetes Mellitus

    Condition: Type 2 Diabetes

    Sponsor: Theratechnologies

    Open on ClinicalTrials.gov ↗
  • NCT01388920 PHASE2 TERMINATED

    A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Two Doses of Tesamorelin in Stable Ambulatory COPD Subjects With Muscle Wasting

    Condition: Chronic Obstructive Pulmonary Disease (COPD)

    Sponsor: Theratechnologies

    Open on ClinicalTrials.gov ↗
  • NCT01591902 PHASE4 TERMINATED

    A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes

    Condition: Diabetic Retinopathy; HIV

    Sponsor: Theratechnologies

    Open on ClinicalTrials.gov ↗
  • NCT01632592 NA WITHDRAWN

    Abdominal Obesity, Cardiovascular Inflammation, and Effects of a Growth Hormone Releasing Hormone Analogue to Reduce Inflammation

    Condition: Abdominal Obesity

    Sponsor: Massachusetts General Hospital

    Open on ClinicalTrials.gov ↗
  • NCT01788462 WITHDRAWN

    Egrifta Replacement and Sleep Disordered Breathing

    Condition: Lipodystrophy

    Sponsor: Johns Hopkins University

    Open on ClinicalTrials.gov ↗
  • NCT02012556 PHASE1 COMPLETED

    A Phase 1 Study to Evaluate the Pharmacokinetics and the Pharmacodynamics of TH9507 Administered Subcutaneously Once Daily for 14 Consecutive Days in HIV Positive Patients

    Condition: HIV

    Sponsor: Theratechnologies

    Open on ClinicalTrials.gov ↗
  • NCT02196831 NA COMPLETED

    Tesamorelin Effects on Liver Fat and Histology in HIV: A Collaborative UO1 Grant

    Condition: Human Immunodeficiency Virus (HIV); Nonalcoholic Fatty Liver Disease (NAFLD); Nonalcoholic Steatohepatitis (NASH)

    Sponsor: Massachusetts General Hospital

    Open on ClinicalTrials.gov ↗
  • NCT02553603 PHASE1 COMPLETED

    The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment

    Condition: Mild Cognitive Impairment

    Sponsor: The University of Texas Medical Branch, Galveston

    Open on ClinicalTrials.gov ↗
  • NCT02572323 PHASE2 COMPLETED

    Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons

    Condition: Mild Cognitive Impairment

    Sponsor: University of California, San Diego

    Open on ClinicalTrials.gov ↗
  • NCT02931474 PHASE2 WITHDRAWN

    The Impact of GHRH on Sleep Promotion and Endocrine Regulation in Service Members Who Sustained a Traumatic Brain Injury and Have Current Insomnia

    Condition: Sleep Disorder; Traumatic Brain Injury

    Sponsor: National Institute of Nursing Research (NINR)

    Open on ClinicalTrials.gov ↗
  • NCT03150511 PHASE2 RECRUITING

    Tesamorelin Therapy to Enhance Axonal Regeneration, Minimize Muscle Atrophy, and Improve Functional Outcomes Following Peripheral Nerve Injury

    Condition: Peripheral Nerve Injuries

    Sponsor: Johns Hopkins University

    Open on ClinicalTrials.gov ↗
  • NCT03375788 PHASE2 COMPLETED

    Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk

    Condition: Non-Alcoholic Fatty Liver Disease; Obesity; Obesity, Abdominal; Liver Fat; Fatty Liver

    Sponsor: Massachusetts General Hospital

    Open on ClinicalTrials.gov ↗
  • NCT03826160 COMPLETED

    Role of Growth Hormone in the Pathogenesis and Treatment of Cardiac Steatosis and Diastolic Dysfunction in HIV

    Condition: Human Immunodeficiency Virus; Lipodystrophy; Cardiac Disease

    Sponsor: Massachusetts General Hospital

    Open on ClinicalTrials.gov ↗
  • NCT07481734 PHASE2 RECRUITING

    A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Tesamorelin (GHRH Analog) for Reducing Hepatic Steatosis in Adults With Metabolic Associated Steatotic Liver Disease (MASLD)

    Condition: Metabolic Associated Steatotic Liver Disease; Nonalcoholic Steatohepatitis; Hepatic Steatosis

    Sponsor: Hudson Biotech

    Open on ClinicalTrials.gov ↗

Doses reported in studies

0 records
This is not a dosing guide. Entries below are historical metadata transcribed verbatim from a cited clinical-trial protocol, published study, or FDA-approved label. They describe what was administered in a specific study population under medical supervision — they are not recommendations, not common-use guidance, and may not be safe or appropriate outside the cited context. Doses widely discussed in community/anecdotal sources are not shown here; see the safety policy for why.

No study-protocol dose records have been curated for Tesamorelin yet. Absence of records is not evidence of safety — many peptides lack adequate human-trial data in the first place.

Records here are populated from public sources only (ClinicalTrials.gov protocol summaries and FDA-approved labels) and must cite a verifiable source URL. They are not added from forum posts, vendor pages, anecdotal write-ups, or social media.

These entries describe what was studied. They do not tell you what to take, how to reconstitute anything, how to fill a capsule, how often to administer, or where to obtain a compound. If you are considering use of Tesamorelin, those decisions belong with a licensed clinician working from the full label or trial record — not from this summary.

Why this page does not list a dose for self-use

The "Doses reported in studies" section above (when populated) describes what was administered in a cited study or label, under medical supervision, in a specific population. It is not a dosing guide for self-use. Separately, we do not publish anecdotal or community-reported dose ranges, administration methods, vial concentrations, or capsule masses for Tesamorelin. Anecdotal figures for unapproved compounds are not harm-reduction data: they lack denominators for adverse events, cannot account for individual physiology or compound purity, and normalise unsupervised use. See the safety policy for the full reasoning.

If this compound has an FDA-approved label

If a label exists, the regulator-reviewed dosing and administration information is there — read it in the context of a prescriber's evaluation.

Questions worth bringing to a clinician

  • What is the evidence for this compound in someone with my history?
  • What are the realistic, regulator-reviewed alternatives?
  • What would you monitor, and what would make you stop?

If you have already taken a peptide and feel unwell: contact emergency services. In the United States, Poison Control is reachable 24/7 at 1-800-222-1222. Do not wait for a community thread.

Research peptides are not substitutes for medical care. If you are considering any peptide for health purposes, speak with a board-certified physician or endocrinologist first.